The 13 references in paper A. Dobrovolsky В., Е. Titaeva V., А. Добровольский Б., Е. Титаева В. (2018) “ЕСТЬ ЛИ ОСНОВАНИЯ ДЛЯ ШИРОКОГО ИСПОЛЬЗОВАНИЯ ТЕСТОВ ОЦЕНКИ ФУНКЦИОНАЛЬНОЙ АКТИВНОСТИ ТРОМБОЦИТОВ В КЛИНИКО-ЛАБОРАТОРНОЙ ПРАКТИКЕ? // ARE THERE ANY REASONS FOR WIDE USE OF PLATELET FUNCTION TESTS IN CLINICAL LABORATORY PRACTICE?” / spz:neicon:aterotromboz:y:2018:i:1:p:140-142

1
Ломакин Н. В., Сумароков А. Б., Доценко Ю. В. и соавт. Индивидуальный подход к применению антитромбоцитарной терапии. На что опереться в решении? Атеротромбоз, 2017, 2: 70–78. / Lomakin NV, Sumarokov AB, Dotsenko YuV, et al. Individual approach to the use of antiplatelet therapy. What to rely on when choosing a solution? Aterotromboz, 2017, 2: 70–78.
(check this in PDF content)
2
Tantry US, Bonello L, Aradi D et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischaemia and bleeding. J Am Coll Cardiol, 2013, 62: 2261–2273.
(check this in PDF content)
3
Price MJ, Berger PB, Teirstein PS et al. Standard- vs highdose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. J Am Med Assoc, 2011, 305: 1097–1105.
(check this in PDF content)
4
Trenk D, Stone GW, Gawaz M et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol, 2012, 59: 2159–2164.
(check this in PDF content)
5
Collet JP, Cuisset T, Range G et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med, 2012, 367: 2100–2109.
(check this in PDF content)
6
Cayla G, Cuisset T, Silvain J et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet, 2016, 388: 2015–2022.
(check this in PDF content)
7
Kirtane AJ, Parikh PB, Stuckey TD et al. Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention? «Window» Analysis From the ADAPT-DES Study (Assessm entofDualAntiPlateletTherapyWithDrug-ElutingStents). J Am Coll Cardiol Intv, 2015, 8: 1978–1987.
(check this in PDF content)
8
Sibbing D, Aradi D, Jacobshagen C et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet, 2017, 390: 1747–1757.
(check this in PDF content)
9
Cuisset T, Deharo P, Quilici J et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J, 2017, 38 (41): 3070–3078.
(check this in PDF content)
10
Cattaneo M. High on-treatment platelet reactivity – definition and measurement. Thromb Haemost, 2013, 109: 792–798.
(check this in PDF content)
11
Aradi D, Storey RF, Komocsi A et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J, 2014, 35: 209–215.
(check this in PDF content)
12
Tantry US, Bonello L, Aradi D et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischaemia and bleeding. J Am Coll Cardiol, 2013, 62: 2261–2273.
(check this in PDF content)
13
Междисциплинарный совет экспертов Российского общества ангиологов и сосудистых хирургов, Российского научного общества специалистов по рентгеноэндоваскулярной диагностике и лечению, Национальной ассоциации по борьбе с инсультами,
(check this in PDF content)